- Wasn't there any other way? First experiences with idarucizumab in Pilsen - case reports2017 | Publication without faculty affiliation
- More safe anticoagulant treatment -Use of idarucizumab (Praxbind(R)): Case reports from RE-VERSE AD study and clinical practice2018 | Third Faculty of Medicine
- Repeated Administration of Idarucizumab to a Patient with Dabigatran Overdose2018 | Faculty of Medicine in Pilsen
- Spontaneous rebound of the anticoagulant effect of accumulated dabigatran after the antagonist activity cessation: Case report of life-threatening haemorrhage2018 | Third Faculty of Medicine
- Treatment of emergencies associated with bleeding risk in patients taking new oral anticoagulants - options concerning termination of their effect2016 | First Faculty of Medicine, Third Faculty of Medicine
- New direct oral anticoagulants2016 | Publication without faculty affiliation
- The first experience with dabigatran antidote in the University Hospital Pilsen2016 | Faculty of Medicine in Pilsen
- Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases2017 | Faculty of Medicine in Hradec Králové
- Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience2018 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Monoklonální protilátky v kardiologii - téma stále aktuálnější2015 | Third Faculty of Medicine
- Therapy of bleeding in association with anticoagulation therapy2019 | Faculty of Medicine in Hradec Králové
- Aggressive treatment of intracerebral hemorrhage with lowering of blood pressure and indication of surgery - YES2018 | Publication without faculty affiliation